Name of journal: *World Journal of  Cardiology*

ESPS Manuscript NO: 8417

Columns: TOPIC HIGHLIGHT

WJC 6th Anniversary Special Issues (1): Hypertension

**Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?**

Vo TM *et al.* Therapies for arterial calcification in chronic kidney disease

Thanh-Mai Vo, Sinee Disthabanchong

**Thanh-Mai Vo,** Division of Nephrology, Saint Louis University, Saint Louis, MO 63103, United States

**Sinee Disthabanchong,** Division of Nephrology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 73170, Thailand

**Author contributions:** Vo TM and Disthabanchong S equally contributed to this paper.

**Correspondence to:**  **Sinee Disthabanchong, MD,** **Associate Professor** of Medicine, Division of Nephrology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, 270 Rama VI Rd, Phayathai, Bangkok, 10400 Thailand. sineemd@hotmail.com

**Telephone:** +66-2-2011116 **Fax:** +66-2-2011400

**Received:** December 27, 2013 **Revised:** March 11, 2014

**Accepted:** April 17, 2014

**Published online:**

**Abstract**

The risk of cardiovascular mortality among patients with end-stage renal disease is several times higher than general population. Arterial calcification, a marker of atherosclerosis and a predictor of cardiovascular mortality, is common in chronic kidney disease (CKD). The presence of traditional cardiovascular risk factors such as diabetes, hypertension, hyperlipidemia, and advanced age cannot fully explain the high prevalence of atherosclerosis and arterial calcification. Other factors specific to CKD such as hyperphosphatemia, excess of calcium, high dose active vitamin D and prolonged dialysis vintage play important roles in the development of arterial calcification. Due to the significant health risk, it is prudent to attempt to lower arterial calcification burden in CKD. Treatment of hyperlipidemia with statin has failed to lower atherosclerotic and arterial calcification burden. Data on diabetes and blood pressure controls as well as smoking cessation on cardiovascular outcomes in CKD population are limited. Currently available treatment options include non-calcium containing phosphate binders, low dose active vitamin D, calcimimetic agent and perhaps bisphosphonates, vitamin K and sodium thiosulfate. Preliminary data on bisphosphonates, vitamin K and sodium thiosulfate are encouraging but larger studies on efficacy and outcomes are needed.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**key words:** Vascular calcification; Coronary calcification; Hemodialysis; Dialysis, Chronic kidney disease

**Core tip:** Arterial calcification is common in chronic kidney disease (CKD). Factors specific to CKD such as hyperphosphatemia, excess of calcium and high dose vitamin D therapy play important roles in the development of arterial calcification. Statin is ineffective in lowering the calcification burden. Data on diabetes and blood pressure controls and smoking cessation on cardiovascular outcomes in CKD population are limited. Available treatment strategies include non-calcium containing phosphate binders, low dose active vitamin D and calcimimetic agent. Preliminary data on bisphosphonates, vitamin K and sodium thiosulfate are encouraging but larger studies on efficacy and outcomes are needed.

Vo TM, Disthabanchong S. Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?

**Available from: URL:**

**DOI:**

**Introduction**

Cardiovascular disease is the leading cause of death in chronic kidney disease (CKD) population. The risk of cardiovascular mortality among those with end-stage renal disease is several times higher than general population[[1](#_ENREF_1)]. Arterial calcification, a marker of atherosclerosis and a predictor of cardiovascular mortality, is common in CKD[[2](#_ENREF_2)]. The presence of arterial calcification leads to an increase in arterial stiffness and a decrease in coronary perfusion resulting in cardiac hypertrophy and myocardial ischemia. Young adults who have been on hemodialysis for a long period of time have the prevalence of coronary artery calcification (CAC) that is at least ten times higher than those of the same age whose kidney function are normal[[3](#_ENREF_3)]. Moreover, an inverse relationship between the estimated glomerular filtration rate and the degree of CAC was observed[[4](#_ENREF_4)]. The presence of traditional cardiovascular risk factors such as diabetes, hypertension, hyperlipidemia, and advanced age cannot fully explain the high prevalence of atherosclerosis and arterial calcification in CKD[[5](#_ENREF_5)]. Along with common cardiovascular risk factors, other factors specific to CKD population such as hyperphosphatemia, excess of calcium from calcium-containing phosphate binders and high calcium concentration in dialysis solution, high dose active vitamin D used in the treatment of hyperparathyroidism and prolonged dialysis vintage have been shown to positively influence the development of arterial calcification[[3](#_ENREF_3),[6](#_ENREF_6)].

**mineral metabolism in CKD**

In early CKD, the kidney’s ability to excrete phosphate load is impaired resulting in a release of fibroblast growth factor 23 (FGF-23) whose action is to stimulate renal phosphate excretion in order to maintain neutral phosphate balance[[7](#_ENREF_7)]. FGF-23, in the presence of its obligatory co-receptor klotho, binds to FGF receptors causing a decrease in phosphate reabsorption in the proximal tubules and a suppression of 1, 25 dihydroxyvitamin D (1, 25-OH2-D) synthesis[[8](#_ENREF_8)]. Continued phosphate retention and decreased 1, 25-OH-D levels later on lead to an increase in parathyroid hormone (PTH) secretion. The accumulation of FGF-23 together with PTH work in concert to enhance renal phosphate excretion. As CKD advances, these compensatory mechanisms fail and phosphate retention ensues evidenced by the development of hyperphosphatemia[[9](#_ENREF_9)]. Accumulation of PTH also enhances bone resorption giving rise to an increase in circulating calcium, bone loss and fracture. On the other hand, elevated FGF-23 has been linked to cardiac hypertrophy, vascular calcification, congestive heart failure and increased mortality[[10-13](#_ENREF_10)].

**Pathogenesis of arterial calcification**

Pathogenesis of arterial calcification is no longer believed to be the passive precipitation of calcium and phosphate crystals but involves a tightly regulated process of cellular transformation of vascular smooth muscle cells (VSMCs) into osteoblast-like cells. These calcified VSMCs, instead of retaining smooth muscle cell markers, express specific osteoblast markers as well as several bone matrix proteins[[14](#_ENREF_14),[15](#_ENREF_15)]. The process of calcification also has features that resemble bone matrix mineralization. For example, the formation and nucleation of mineral crystals require the presence of matrix vesicles. Dying VSMCs form apoptotic bodies which have the ability to concentrate calcium and phosphate in the same fashion as matrix vesicles[[16](#_ENREF_16)]. Several factors related to CKD including high calcium and phosphate environment and high dose active vitamin D have been shown to promote VSMC transformation followed by matrix vesicle-mediated mineralization[[17](#_ENREF_17),[18](#_ENREF_18)]. Moreover, the reduction and the alteration of function of naturally occurring calcification inhibitors such as fetuin A, matrix gla-protein, osteopontin and osteoprotegerin are also important in the development of arterial calcification in CKD[[19](#_ENREF_19),[20](#_ENREF_20)]. Klotho deficiency has been observed in kidneys, parathyroid glands and other organs during the course of CKD[[21](#_ENREF_21),[22](#_ENREF_22)]. In arterial wall, decreased klotho expression potentiates the development of arterial calcification[[23](#_ENREF_23),[24](#_ENREF_24)]. The role of FGF-23 in arterial calcification is complex. Few studies have identified FGF receptor and its signaling pathway in the arterial wall whereas others have not[[12](#_ENREF_12),[23](#_ENREF_23),[25](#_ENREF_25)]. Kidney transplantation can markedly improve both renal function and mineral metabolism in the long term. Several studies have demonstrated stabilization or decline in the rate of progression of arterial calcification in patients who received a kidney transplant as compared to those who remained on dialysis especially during the first 1-2 years[[26-28](#_ENREF_26)]. However, with longer follow-up period up to 3-4 years post-transplantation, the progression becomes more evident. Overall the rate of CAC progression was estimated to be around 10% per year[[29](#_ENREF_29),[30](#_ENREF_30)]. The severity of baseline calcification and the presence of hyperlipidemia were identified as independent predictors of progression in these studies. It appears that once calcification develops it probably cannot be reversed. Despite the significant improvement in kidney function and mineral metabolism, arterial calcification tends to become more severe as time passes probably triggering by the presence of common cardiovascular risk factors in kidney transplant recipients including aging, diabetes, hypertension and hyperlipidemia.

Due to the significant health risk of atherosclerosis and arterial calcification, it is prudent to attempt to lower calcification burden in CKD patients. Cardiovascular risk modification through the use of statin for hyperlipidemia has not been proved fruitful in attenuating CAC progression[[31](#_ENREF_31),[32](#_ENREF_32)]. Studies on diabetes and blood pressure controls as well as smoking cessation on cardiovascular outcomes in CKD population are limited. The following review focuses on therapies that can modify CKD-related risk factors for arterial calcification which may have favorable impact on cardiovascular outcomes.

**Phosphate binders**

The purpose of phosphate binder is to bind phosphate in the ingested food and increase its elimination in the stool. Calcium-containing phosphate binders such as calcium carbonate and calcium acetate are commonly used as phosphate binding agents since early 1980s as alternatives to aluminum hydroxide due to the high prevalence of aluminum toxicity. The use of calcium-containing phosphate binders is often limited by the development of hypercalcemia. Furthermore, over the past decade, increasing evidence have linked the amount of calcium intake derived from calcium-containing phosphate binders to the severity of vascular calcification[[3](#_ENREF_3),[6](#_ENREF_6),[33](#_ENREF_33)]. Newer phosphate binding agents including sevelamer, lanthanum, calcium-magnesium combination and iron-based phosphate binders have been developed to overcome these limitations.

***Sevelamer carbonate***

Sevelamer is an ion-exchange resin that is commonly used as an alternative to calcium for phosphate binding. In addition to binding to phosphate, sevelamer has been shown to lower cholesterol, FGF-23, inflammatory markers, c-reactive protein and hemoglobin A1C and may improve endothelial function[[34](#_ENREF_34),[35](#_ENREF_35)]. In hemodialysis patients, sevelamer attenuates the progression of CAC and aortic calcification compared to calcium[[36-38](#_ENREF_36)] (Table 1). In two randomized controlled trials in incident hemodialysis patients, those who were treated with calcium had a greater risk of death compared to sevelamer[[2](#_ENREF_2),[39](#_ENREF_39)]. However, a randomized study in prevalent hemodialysis patients did not show survival benefit associated with sevelamer use[[40](#_ENREF_40)]. In non-dialysis CKD population, patients who were treated with sevelamer in order to keep serum phosphate within the normal range had better survival compared to those treated with calcium[[41](#_ENREF_41)]. In another small randomized study in moderate CKD patients that compared calcium, sevelamer and lanthanum versus placebo revealed an increase in arterial calcification in all groups, however, the degree was highest in the calcium group[[42](#_ENREF_42)]. It has been theorized that the use of phosphate binders in non-dialysis CKD may result in an increase in the availability of free calcium in the intestine. Similarly, when rosuvastatin, sevelamer and no drug were compared in a small randomized study in moderate CKD patients, a significant increase in CAC scores was observed in all three groups[[43](#_ENREF_43)]. Despite the possible survival benefit, the use of phosphate binders may not be beneficial in reducing calcification burden in moderate CKD population. In order to justify the use of phosphate binders in non-dialysis CKD patients, more studies are required to confirm the beneficial or harmful effects.

***Lanthanum carbonate***

Lanthanum is a rare earth element that is as effective as aluminum and better than sevelamer in binding phosphate[[44](#_ENREF_44)]. Long-term use of lanthanum in renal failure can result in an accumulation in various organs but without any obvious harmful effects[[45](#_ENREF_45),[46](#_ENREF_46)]. Similar to sevelamer, the use of lanthanum in moderate CKD can lower FGF-23 levels[[47](#_ENREF_47)]. In both uremic rats and dialysis patients, lanthanum attenuated the development of vascular calcification[[48](#_ENREF_48),[49](#_ENREF_49)]. The data on patient-level outcomes are limited. A follow-up data on dialysis patients who were enrolled in the phase 3 study did not show survival benefit associated with lanthanum treatment. However, in a subgroup of patients > 65 years of age, those who received lanthanum carbonate appeared to have better survival compared to standard therapy[[50](#_ENREF_50)]. The efficacy of lanthanum depends largely on the pills being chewed thoroughly prior to swallowing. Recently the company has developed the oral powder form that may work better in patients with problems with mastication.

***Combined calcium acetate-magnesium carbonate***

Both intracellular and extracellular magnesium are vital in preventing inflammation and oxidative stress. Decreased magnesium concentration is associated with impaired endothelial function, vasospasm and atherogenesis[[51](#_ENREF_51)]. Increased severity of vascular calcification has been observed in hemodialysis and peritoneal dialysis patients with low normal magnesium levels[[52](#_ENREF_52)]. *In vitro* studies and *in vivo* study in rodents demonstrated that increasing magnesium concentrations were protective against vascular calcification through upregulation of anti-calcification proteins[[53-55](#_ENREF_53)]. In a study of 204 hemodialysis patients over a 24-wk follow-up, the European formulation of combined calcium-magnesium phosphate binder (calcium acetate 435 mg/magnesium carbonate 235 mg) was as efficacious as sevelamer in reducing serum phosphate without the side effect of increased serum ionized calcium. A small but significant increase in serum magnesium was observed. All patients were dialyzed against 0.5 mm magnesium dialysate and experienced no serious adverse events[[56](#_ENREF_56)]. FGF-23 levels also decreased in the magnesium group[[57](#_ENREF_57)]. Furthermore, a small observational study in 7 hemodialysis patients showed stabilization of CAC score after 18 mo of being on calcium-magnesium phosphate binder[[58](#_ENREF_58)].

***Iron-based phosphate binders***

Recently [food and drug administration](http://suoxie.911cha.com/bTJx.html) (FDA) approved iron-based phosphate binder in the United States is sucroferric oxyhydroxide. Another preparation of iron-based phosphate binder, ferric citrate, is currently under review by the FDA. These drugs are as efficacious as sevelamer in lowering serum phosphate[[59](#_ENREF_59),[60](#_ENREF_60)]. The use of iron-based phosphate binder is associated with an increase in serum ferritin and percent transferrin saturation leading to lesser requirement of intravenous iron and erythropoiesis-stimulating agents in dialysis patients[[61](#_ENREF_61)]. Iron deficiency can increase FGF-23 levels and therefore iron-based phosphate binders can lower FGF-23[[62](#_ENREF_62)]. In uremic rats, sucroferric oxyhydroxide prevented the development of vascular calcification[[63](#_ENREF_63)]. More information regarding iron-based phosphate binders should become available within the next year.

**Active Vitamin D**

Active vitamin D are primarily used for the treatment of hyperparathyroidism in CKD. In addition to lowering PTH, active vitamin D also stimulates calcium and phosphate absorption in the gastrointestinal tract and therefore can result in worsening hypercalcemia and hyperphosphatemia. Active vitamin D also reduces proteinuria, augments the response to erythropoietin and suppresses renin-angiotensin system[[64-66](#_ENREF_64)]. The parent drug of active vitamin D is calcitriol or 1, 25-dihydroxyvitamin D3. The closely related analogs to calcitriol are alfacalcidol (1-alpha hydroxyvitamin D3) and doxercalciferol (1-alpha hydroxyvitamin D2). Both require 25-hydroxylation process in the liver prior to becoming active forms. Similar to the parent compound, alfacalcidol and doxercalciferol can precipitate hypercalcemia and hyperphosphatemia especially if given in high doses. Paricalcitol or 19-Nor-1-25-dihydroxyvitamin D2 was developed specifically for the treatment of hyperparathyroidism in CKD. Paricalcitol appears to act preferentially in the parathyroid glands and less so in the gastrointestinal tract[[67](#_ENREF_67)]. In rodents with uremia, administration of calcitriol and doxercalciferol resulted in an increase in aortic calcification, whereas paricalcitol did not[[68](#_ENREF_68)]. However when testing different doses of calcitriol and paricalcitol, both active vitamin D in high doses induced a similar degree of aortic calcification. Interestingly, in this study, lower doses of both calcitriol and paricalcitol seemed to be protective against vascular calcification[[69](#_ENREF_69)]. The calcemic and phosphatemic effects of all forms of active vitamin D have been confirmed in a recent randomized crossover trial in hemodialysis patients that showed similar incidences of hyperphosphatemia and hypercalcemia among patients who received alfacalcidol or paricalcitol[[70](#_ENREF_70)]. The increase in calcium and phosphate load as a result of active vitamin D induced calcium and phosphate absorption is likely responsible for the development of vascular calcification. On the other hand, the direct effect of vitamin D on vascular wall appears to be positive. Active vitamin D can stimulate klotho and osteopontin expression in the arterial wall. Both of which help prevent vascular calcification[[71](#_ENREF_71)]. This finding can probably explain the protective effect of low dose active vitamin D on vascular calcification. The development of vascular calcification associated with the use of active vitamin D is the result of systemic accumulation of calcium and phosphate rather than the local effect on arterial wall[[72](#_ENREF_72)]. Therefore, low doses of active vitamin D that do not augment calcium and phosphate load may actually be protective against vascular calcification[[23](#_ENREF_23),[69](#_ENREF_69)].

As for the beneficial effect of vitamin D on renin-angiotensin system, a study in rats with renal failure demonstrated that active vitamin D treatment could prevent left ventricular hypertrophy and myocardial fibrosis[[73](#_ENREF_73)]. In an observational study in hemodialysis patients, treatment of hyperparathyroidism with intravenous calcitriol led to a decline in renin, angiotensin II and atrial natriuretic peptide levels associated with a decrease in left ventricular hypertrophy[[74](#_ENREF_74)]. However, a recent randomized study in moderate CKD patients revealed only a non-significant trend toward a decrease in left ventricular mass index in the group of patients that received paricalcitol[[75](#_ENREF_75)]. Nevertheless, subsequent analysis did demonstrate a significant decrease in left atrial volume index[[76](#_ENREF_76)]. The lack of clear benefit of active vitamin D on cardiac hypertrophy may be related to the increase in FGF-23 in response to active vitamin D treatment. As for survival benefit of active vitamin D therapy in hemodialysis patients, several retrospective and observational studies have revealed a decrease in all-cause and cardiovascular mortality among patients who received active vitamin D regardless of PTH levels[[77](#_ENREF_77) ]. Details of these studies can be found in Table 1. The benefit seemed to be more pronounced in the low-dose range and among patients who received paricalcitol. At the present time, there is no published prospective randomized study that evaluates the effect of active vitamin D on survival in CKD population.

**Calcimimetic**

Calcimimetic allosterically activates calcium-sensing receptors, thus can suppress PTH secretion without elevating serum calcium. Calcimimetic is used as an add-on to active vitamin D and phosphate binder in the treatment of hyperparathyroidism in CKD[[78](#_ENREF_78)]. Currently, cinacalcet is the only calcimimetic drug available for this purpose. In nephrectomized rats, adding cinacalcet to active vitamin D helped decrease the severity of vascular calcification associated with high dose vitamin D treatment[[79](#_ENREF_79)]. In a randomized study in 360 hemodialysis patients, the rate of progression of CAC and aortic valve calcification was reduced when cinacalcet was added to low dose active vitamin D compared to larger and varying doses of active vitamin D therapy alone[[80](#_ENREF_80),[81](#_ENREF_81)]. Cinacalcet therapy also decreases FGF-23 levels[[82](#_ENREF_82)]. However, significant benefits in terms of overall survival or cardiovascular events were not observed in a large randomized controlled trial in 3,883 hemodialysis patients after 5 years of follow-up[[83](#_ENREF_83)].

**Bisphosphonates**

Bisphosphonates are synthetic analogs of inorganic pyrophosphate that have the ability to suppress bone resorption and therefore are commonly used in the treatment and prevention of osteoporosis in general population. The other important property of inorganic pyrophosphate is inhibition of calcium and phosphate crystal deposition in the bone matrix. Oral etidronate and intravenous pamidronate have been utilized in the treatment of calcific uremic arteriolopathy (CUA), a condition of wide spread small-vessel calcification that results in progressive cutaneous ulcer due to ischemia[[84](#_ENREF_84),[85](#_ENREF_85)]. In uremic rats, daily pamidronate or etidronate therapies prevented aortic calcification[[86](#_ENREF_86)]. In hemodialysis patients, oral and parenteral etidronate have been shown to delay the progression of CAC and aortic calcification[[87](#_ENREF_87),[88](#_ENREF_88)]. However, this anti-calcification effect was not observed with the newer generation bisphosphonates including alendronate and ibandronate[[89](#_ENREF_89),[90](#_ENREF_90)]. A recent randomized study in general population with hypercholesterolemia revealed the combined regimen of daily atorvastatin and etidronate reduced atherosclerotic plaque burden in thoracic and abdominal aorta[[91](#_ENREF_91)]. It was suggested that etidronate was responsible for the regression of calcified plaques in abdominal aorta while atorvastatin attenuating the non-calcified plaques in thoracic aorta. Worsening adynamic bone disease with the use of bisphosphonates in the setting of CKD is of concern, thus recent Kidney Disease Improving Global Outcomes (KDIGO) recommendation advised against prescribing bisphosphonates in patients with an eGFR < 30 mL/min per 1.73 m2[[92](#_ENREF_92)].

**Sodium Thiosulfate**

Sodium thiosulfate (STS) is a reducing, chelating and anti-oxidant agent that is useful as an antidote in cyanide poisoning. STS also has the ability to chelate calcium in precipitated minerals forming calcium thiosulfate that is more soluble than calcium oxalate and calcium phosphate. Thus its use has been expanded in conditions with increased calcification burden such has nephrolithiasis, metastatic calcification, tumoral calcinosis and CUA[[93-96](#_ENREF_93)]. In a large observational study in 172 hemodialysis patients with CUA, intravenous STS therapy resulted in clinical improvement in most patients[[96](#_ENREF_96)]. In uremic rats, parenteral administration of STS has been shown to prevent the development of vascular calcification[[97](#_ENREF_97)]. Twice weekly intravenous STS therapy in hemodialysis patients was able to delay the rate of progression of CAC after six months compared to the non-treatment group but with a significant decline in hip BMD in one study[[33](#_ENREF_33),[98](#_ENREF_98)]. Long-term intravenous or intraperitoneal STS therapy in dialysis patients are well tolerated with minimal side effects[[33](#_ENREF_33),[96](#_ENREF_96),[99](#_ENREF_99)]. The mechanism by which STS reduces calcification burden is poorly understood. It has been suggested that mechanisms other than calcium chelation are responsible for the decreased calcification burden[[94](#_ENREF_94),[100](#_ENREF_100)].

**Vitamin K**

There are two types of naturally occurring vitamin K: vitamin K1 (phylloquinone) found mostly in green leafy vegetables and vegetable oils and vitamin K2 (menaquinone) found in animals, bacteria, and fermented food such as cheese and natto. Five to twenty five percent of ingested vitamin K1 can be converted to vitamin K2 in the body. Colonic bacteria can synthesize vitamin K2 and antibiotics that interfere with the growth of these colonic flora impair vitamin K2 production[[101](#_ENREF_101)]. Vitamin K is required as a co-factor in the process of gamma-carboxylation of several extracellular matrix proteins turning inactive uncarboxylated proteins into active carboxylated forms. Prothrombin, coagulation factors 7, 9 and 10 require vitamin K1 for their carboxylation processes; whereas, osteocalcin and matrix gla-protein require vitamin K2[[102](#_ENREF_102)]. Osteocalcin is important in bone mineralization; therefore, menaquinone is used in the treatment of osteoporosis. Matrix gla-protein is a calcification inhibitor that plays important role in the prevention of arterial calcification. Warfarin, an antagonist to vitamin K, not only inhibits coagulation but long-term use can also promote arterial calcification[[103](#_ENREF_103)]. Vitamin K deficiency is common in end-stage renal disease patients and the accumulation of inactive form of matrix gla-protein is associated with an increase in the severity of arterial calcification and mortality[[104](#_ENREF_104),[105](#_ENREF_105)]. High menaquinone intake is also associated with reduced CAC and coronary heart disease in general population[[106](#_ENREF_106),[107](#_ENREF_107)]. Vitamin K1 or K2 supplementation especially in high doses can significantly decrease the amount of inactive matrix gla-protein in hemodialysis patients[[108](#_ENREF_108)]. In CKD rats treated with warfarin, high dietary vitamin K1 can blunt the development of vascular calcification[[109](#_ENREF_109)]. The favorable impact of vitamin K1 on vascular calcification is likely depending on the conversion of vitamin K1 to vitamin K2 in the body. A prospective randomized controlled trial to evaluate the effect vitamin K1 supplementation on the progression of CAC (VitaVasK trial) in hemodialysis patients is currently ongoing[[110](#_ENREF_110)].

In conclusion, the currently available treatment options for arterial calcification in CKD include non-calcium containing phosphate binders, low doses of active vitamin D, calcimimetic agent and perhaps bisphosphonates, vitamin K and STS. Preliminary data on bisphosphonates, vitamin K and STS are encouraging but larger studies on efficacy and outcomes are needed.

**REFERENCES**

1 **Foley RN**, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 1998; **32**: S112-S119 [PMID: 9820470]

2 **Block GA**, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. *Kidney Int* 2007; **71**: 438-441 [PMID: 17200680 DOI: 10.1038/sj.ki.5002059]

3 **Goodman WG**, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N Engl J Med* 2000; **342**: 1478-1483 [PMID: 10816185 DOI: 10.1056/NEJM200005183422003]

4 **Budoff MJ**, Rader DJ, Reilly MP, Mohler ER, Lash J, Yang W, Rosen L, Glenn M, Teal V, Feldman HI. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. *Am J Kidney Dis* 2011; **58**: 519-526 [PMID: 21783289 DOI: 10.1053/j.ajkd.2011.04.024]

5 **Longenecker JC**, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. *J Am Soc Nephrol* 2002; **13**: 1918-1927 [PMID: 12089389]

6 **London GM**, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant* 2003; **18**: 1731-1740 [PMID: 12937218]

7 **Isakova T**, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. *Kidney Int* 2011; **79**: 1370-1378 [PMID: 21389978 DOI: 10.1038/ki.2011.47]

8 **Shimada T**, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. *JBMR* 2004; 19(3): 429-435

9 **Chartsrisak K**, Vipattawat K, Assanatham M, Nongnuch A, Ingsathit A, Domrongkitchaiporn S, Sumethkul V, Distha-Banchong S. Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients. *BMC Nephrol* 2013; **14**: 14 [PMID: 23324569 DOI: 10.1186/1471-2369-14-14]

10 **Faul C**, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. *J Clin Invest* 2011; **121**: 4393-4408 [PMID: 21985788 DOI: 10.1172/JCI46122]

11 **Scialla JJ**, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M. Fibroblast growth factor-23 and cardiovascular events in CKD. *J Am Soc Nephrol* 2014; **25**: 349-360 [PMID: 24158986 DOI: 10.1681/ASN.2013050465]

12 **Jimbo R**, Kawakami-Mori F, Mu S, Hirohama D, Majtan B, Shimizu Y, Yatomi Y, Fukumoto S, Fujita T, Shimosawa T. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. *Kidney Int* 2013 [PMID: 24088960 DOI: 10.1038/ki.2013.332]

13 **Isakova T**, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. *JAMA* 2011; **305**: 2432-2439 [PMID: 21673295 DOI: 10.1001/jama.2011.826]

14 **Moe SM**, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. *Kidney Int* 2002; **61**: 638-647 [PMID: 11849407 DOI: 10.1046/j.1523-1755.2002.00170.x]

15 **Disthabanchong S.** Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication. *World J Nephrol* 2012; **1**: 43-53 [PMID: 24175241 DOI: 10.5527/wjn.v1.i2.43]

16 **Proudfoot D**, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. *Circ Res* 2000; **87**: 1055-1062 [PMID: 11090552]

17 **Cardús A**, Panizo S, Parisi E, Fernandez E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. *J Bone Miner Res* 2007; **22**: 860-866 [PMID: 17352647 DOI: 10.1359/jbmr.070305]

18 **Yang H**, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. *Kidney Int* 2004; **66**: 2293-2299 [PMID: 15569318 DOI: 10.1111/j.1523-1755.2004.66015.x]

19 **Ketteler M**, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. *Lancet* 2003; **361**: 827-833 [PMID: 12642050 DOI: 10.1016/S0140-6736(03)12710-9]

20 **Shanahan CM**, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME. Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. *Circulation* 1999; **100**: 2168-2176 [PMID: 10571976]

21 **Koh N**, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, Sugimura K, Kishimoto T, Kinoshita S, Kuroki T, Nabeshima Y. Severely reduced production of klotho in human chronic renal failure kidney. *Biochem Biophys Res Commun* 2001; **280**: 1015-1020 [PMID: 11162628 DOI: 10.1006/bbrc.2000.4226]

22 **Komaba H**, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu K, Nakagawa K, Tsugawa N, Okano T, Kitazawa R, Fukagawa M, Kita T. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. *Kidney Int* 2010; **77**: 232-238 [PMID: 19890272 DOI: 10.1038/ki.2009.414]

23 **Lim K**, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. *Circulation* 2012; **125**: 2243-2255 [PMID: 22492635 DOI: 10.1161/CIRCULATIONAHA.111.053405]

24 **Hu MC**, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, Moe OW. Klotho deficiency causes vascular calcification in chronic kidney disease. *J Am Soc Nephrol* 2011; **22**: 124-136 [PMID: 21115613 DOI: 10.1681/ASN.2009121311]

25 **Scialla JJ**, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. *Kidney Int* 2013; **83**: 1159-1168 [PMID: 23389416 DOI: 10.1038/ki.2013.3]

26 **Oschatz E**, Benesch T, Kodras K, Hoffmann U, Haas M. Changes of coronary calcification after kidney transplantation. *Am J Kidney Dis* 2006; **48**: 307-313 [PMID: 16860198 DOI: S0272-6386(06)00755-4]

27 **Bargnoux AS**, Dupuy AM, Garrigue V, Jaussent I, Gahide G, Badiou S, Szwarc I, Deleuze S, Vernhet H, Cristol JP, Mourad G. Evolution of coronary artery calcifications following kidney transplantation: relationship with osteoprotegerin levels. *Am J Transplant* 2009; **9**: 2571-2579 [PMID: 19775319 DOI: 10.1111/j.1600-6143.2009.02814.x]

28 **Mazzaferro S**, Pasquali M, Taggi F, Baldinelli M, Conte C, Muci ML, Pirozzi N, Carbone I, Francone M, Pugliese F. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. *Clin J Am Soc Nephrol* 2009; **4**: 685-690 [PMID: 19211668 DOI: 10.2215/CJN.03930808]

29 **Maréchal C**, Coche E, Goffin E, Dragean A, Schlieper G, Nguyen P, Floege J, Kanaan N, Devuyst O, Jadoul M. Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients. *Am J Kidney Dis* 2012; **59**: 258-269 [PMID: 21944666 DOI: 10.1053/j.ajkd.2011.07.019]

30 **Seyahi N**, Cebi D, Altiparmak MR, Akman C, Ataman R, Pekmezci S, Serdengecti K. Progression of coronary artery calcification in renal transplant recipients. *Nephrol Dial Transplant* 2012; **27**: 2101-2107 [PMID: 21965591 DOI: 10.1093/ndt/gfr558]

31 **Schmermund A**, Achenbach S, Budde T, Buziashvili Y, Förster A, Friedrich G, Henein M, Kerkhoff G, Knollmann F, Kukharchuk V, Lahiri A, Leischik R, Moshage W, Schartl M, Siffert W, Steinhagen-Thiessen E, Sinitsyn V, Vogt A, Wiedeking B, Erbel R. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. *Circulation* 2006; **113**: 427-437 [PMID: 16415377 DOI: 10.1161/CIRCULATIONAHA.105.568147]

32 **Arad Y**, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. *J Am Coll Cardiol* 2005; **46**: 166-172 [PMID: 15992652 DOI: 10.1016/j.jacc.2005.02.089]

33 **Adirekkiat S**, Sumethkul V, Ingsathit A, Domrongkitchaiporn S, Phakdeekitcharoen B, Kantachuvesiri S, Kitiyakara C, Klyprayong P, Disthabanchong S. Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. *Nephrol Dial Transplant* 2010; **25**: 1923-1929 [PMID: 20083471 DOI: 10.1093/ndt/gfp755]

34 **Vlassara H**, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. *Clin J Am Soc Nephrol* 2012; **7**: 934-942 [PMID: 22461535 DOI: 10.2215/CJN.12891211]

35 **Guida B**, Cataldi M, Riccio E, Grumetto L, Pota A, Borrelli S, Memoli A, Barbato F, Argentino G, Salerno G, Memoli B. Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study. *PLoS One* 2013; **8**: e73558 [PMID: 24015307 DOI: 10.1371/journal.pone.0073558]

36 **Chertow GM**, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int* 2002; **62**: 245-252 [PMID: 12081584 DOI: 10.1046/j.1523-1755.2002.00434.x]

37 **Kakuta T**, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. *Am J Kidney Dis* 2011; **57**: 422-431 [PMID: 21239096 DOI: 10.1053/j.ajkd.2010.10.055]

38 **Braun J**, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification. *Clin Nephrol* 2004; **62**: 104-115 [PMID: 15356967]

39 **Di Iorio B**, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, Bellasi A. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. *Am J Kidney Dis* 2013; **62**: 771-778 [PMID: 23684755 DOI: 10.1053/j.ajkd.2013.03.023]

40 **Suki WN**, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. *Kidney Int* 2007; **72**: 1130-1137 [PMID: 17728707 DOI: 10.1038/sj.ki.5002466]

41 **Di Iorio B**, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. *Clin J Am Soc Nephrol* 2012; **7**: 487-493 [PMID: 22241819 DOI: 10.2215/CJN.03820411]

42 **Block GA**, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM. Effects of phosphate binders in moderate CKD. *J Am Soc Nephrol* 2012; **23**: 1407-1415 [PMID: 22822075 DOI: 10.1681/ASN.2012030223]

43 **Lemos MM**, Watanabe R, Carvalho AB, Jancikic AD, Sanches FM, Christofalo DM, Draibe SA, Canziani ME. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. *Clin Nephrol* 2013; **80**: 1-8 [PMID: 23442255 DOI: 10.5414/CN107630]

44 **Daugirdas JT**, Finn WF, Emmett M, Chertow GM. The phosphate binder equivalent dose. *Semin Dial* ; **24**: 41-49 [PMID: 21338393 DOI: 10.1111/j.1525-139X.2011.00849.x]

45 **Altmann P**, Barnett ME, Finn WF. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. *Kidney Int* 2007; **71**: 252-259 [PMID: 17035945 DOI: 10.1038/sj.ki.5001932]

46 **Ben-Dov IZ**, Pappo O, Sklair-Levy M, Galitzer H, Ilan Y, Naveh-Many T, Silver J. Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. *Nephrol Dial Transplant* 2007; **22**: 362-368 [PMID: 17090605 DOI: 10.1093/ndt/gfl623]

47 **Gonzalez-Parra E**, Gonzalez-Casaus ML, Galán A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. *Nephrol Dial Transplant* 2011; **26**: 2567-2571 [PMID: 21436379 DOI: 10.1093/ndt/gfr144]

48 **Neven E**, Postnov P, De Clerck N, De Broe ME, D'Haese PC, Persy V. Lanthanum carbonate treatment prevents the development of vascular calcification in rats with adenine-induced chronic renal failure. *J Am Soc Nephrol* 2007; **18**(Abstract Issue): 743A-744A

49 **Toussaint ND**, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. *Nephrology (Carlton)* 2011; **16**: 290-298 [PMID: 21342323 DOI: 10.1111/j.1440-1797.2010.01412.x]

50 **Wilson R**, Zhang P, Smyth M, Pratt R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. *Curr Med Res Opin* 2009; **25**: 3021-3028 [PMID: 19845495 DOI: 10.1185/03007990903399398]

51 **Maier JA**. Low magnesium and atherosclerosis: an evidence-based link. *Mol Aspects Med* ; **24**: 137-146 [PMID: 12537993 DOI: S009829970200095X]

52 **Ishimura E**, Okuno S, Kitatani K, Tsuchida T, Yamakawa T, Shioi A, Inaba M, Nishizawa Y. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. *Clin Nephrol* 2007; **68**: 222-227 [PMID: 17969489]

53 **Montezano AC**, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, Wadhera V, van Leeuwen FN, Touyz RM. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. *Hypertension* 2010; **56**: 453-462 [PMID: 20696983 DOI: 10.1161/HYPERTENSIONAHA.110.152058]

54 **Louvet L**, Büchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. *Nephrol Dial Transplant* 2013; **28**: 869-878 [PMID: 23229924 DOI: 10.1093/ndt/gfs520]

55 **De Schutter TM**, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D'Haese PC, Neven E. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. *Kidney Int* 2013; **83**: 1109-1117 [PMID: 23486515 DOI: 10.1038/ki.2013.34]

56 **de Francisco AL**, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. *Nephrol Dial Transplant* 2010; **25**: 3707-3717 [PMID: 20530499 DOI: 10.1093/ndt/gfq292]

57 **Covic A**, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, Ponce P, Marzell B, de Francisco AL. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. *Nephrol Dial Transplant* 2013; **28**: 2383-2392 [PMID: 23787550 DOI: 10.1093/ndt/gft203]

58 **Spiegel DM**, Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. *Hemodial Int* 2009; **13**: 453-459 [PMID: 19469885 DOI: 10.1111/j.1542-4758.2009.00364.x]

59 **Wüthrich RP**, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. *Clin J Am Soc Nephrol* 2013; **8**: 280-289 [PMID: 23124782 DOI: 10.2215/CJN.08230811]

60 **Yokoyama K**, Hirakata H, Akiba T, Sawada K, Kumagai Y. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. *Am J Nephrol* 2012; **36**: 478-487 [PMID: 23147696 DOI: 10.1159/000344008]

61 **Mutell R**, Rubin JL, Bond TC, Mayne T. Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. *Int J Nephrol Renovasc Dis* 2013; **6**: 79-87 [PMID: 23662073 DOI: 10.2147/IJNRD.S40729]

62 **Wolf M**, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. *J Bone Miner Res* 2013; **28**: 1793-1803 [PMID: 23505057 DOI: 10.1002/jbmr.1923]

63 **Phan O**, Maillard M, Peregaux C, Mordasini D, Stehle JC, Funk F, Burnier M. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats. *J Pharmacol Exp Ther* 2013; **346**: 281-289 [PMID: 23697346 DOI: 10.1124/jpet.113.204792]

64 **Icardi A**, Paoletti E, De Nicola L, Mazzaferro S, Russo R, Cozzolino M. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. *Nephrol Dial Transplant* 2013; **28**: 1672-1679 [PMID: 23468534 DOI: 10.1093/ndt/gft021]

65 **de Borst MH**, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. *J Am Soc Nephrol* 2013; **24**: 1863-1871 [PMID: 23929770 DOI: 10.1681/ASN.2013030203]

66 **Li YC**, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* 2002; **110**: 229-238 [PMID: 12122115 DOI: 10.1172/JCI15219]

67 **Sprague SM**, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. *Kidney Int* 2003; **63**: 1483-1490 [PMID: 12631365 DOI: 10.1046/j.1523-1755.2003.00878.x]

68 **Mizobuchi M**, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. *Kidney Int* 2007; **72**: 709-715 [PMID: 17597697 DOI: 10.1038/sj.ki.5002406]

69 **Mathew S**, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. *J Am Soc Nephrol* 2008; **19**: 1509-1519 [PMID: 18448587 DOI: 10.1681/ASN.2007080902]

70 **Hansen D**, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen TG, Madsen JK, Tougaard BG, Marckmann P, Thye-Roenn P, Nielsen JE, Kreiner S, Brandi L. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. *Kidney Int* 2011; **80**: 841-850 [PMID: 21832979 DOI: 10.1038/ki.2011.226]

71 **Lau WL**, Leaf EM, Hu MC, Takeno MM, Kuro-o M, Moe OW, Giachelli CM. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. *Kidney Int* 2012; **82**: 1261-1270 [PMID: 22932118 DOI: 10.1038/ki.2012.322]

72 **Lomashvili KA**, Wang X, O'Neill WC. Role of local versus systemic vitamin D receptors in vascular calcification. *Arterioscler Thromb Vasc Biol* 2014; **34**: 146-151 [PMID: 24202304 DOI: 10.1161/ATVBAHA.113.302525]

73 **Panizo S**, Barrio-Vázquez S, Naves-Díaz M, Carrillo-López N, Rodríguez I, Fernández-Vázquez A, Valdivielso JM, Thadhani R, Cannata-Andía JB. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. *Nephrol Dial Transplant* 2013; **28**: 2735-2744 [PMID: 24013683 DOI: 10.1093/ndt/gft268]

74 **Park CW**, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. *Am J Kidney Dis* 1999; **33**: 73-81 [PMID: 9915270 DOI: S0272-6386(99)70260-X]

75 **Thadhani R**, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. *JAMA* 2012; **307**: 674-684 [PMID: 22337679 DOI: 10.1001/jama.2012.120]

76 **Tamez H**, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. *Am Heart J* 2012; **164**: 902-909 [PMID: 23194491 DOI: 10.1016/j.ahj.2012.09.018]

77 **Duranton F**, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daurès JP, Argilés A. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. *Am J Nephrol* 2013; **37**: 239-248 [PMID: 23467111 DOI: 10.1159/000346846]

78 **Block GA**, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. *N Engl J Med* 2004; **350**: 1516-1525 [PMID: 15071126 DOI: 10.1056/NEJMoa031633]

79 **De Schutter TM**, Behets GJ, Jung S, Neven E, D'Haese PC, Querfeld U. Restoration of bone mineralization by cinacalcet is associated with a significant reduction in calcitriol-induced vascular calcification in uremic rats. *Calcif Tissue Int* 2012; **91**: 307-315 [PMID: 22926202 DOI: 10.1007/s00223-012-9635-0]

80 **Raggi P**, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. *Nephrol Dial Transplant* 2011; **26**: 1327-1339 [PMID: 21148030 DOI: 10.1093/ndt/gfq725]

81 **Ureña-Torres P**, Bridges I, Christiano C, Cournoyer SH, Cooper K, Farouk M, Kopyt NP, Rodriguez M, Zehnder D, Covic A. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. *Nephrol Dial Transplant* 2013; **28**: 1241-1254 [PMID: 23328710 DOI: 10.1093/ndt/gfs568]

82 **Koizumi M**, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. *Nephrol Dial Transplant* 2012; **27**: 784-790 [PMID: 21730210 DOI: 10.1093/ndt/gfr384]

83 **Chertow GM**, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. *N Engl J Med* 2012; **367**: 2482-2494 [PMID: 23121374 DOI: 10.1056/NEJMoa1205624]

84 **Monney P**, Nguyen QV, Perroud H, Descombes E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. *Nephrol Dial Transplant* 2004; **19**: 2130-2132 [PMID: 15252173 DOI: 10.1093/ndt/gfh305]

85 **Shiraishi N**, Kitamura K, Miyoshi T, Adachi M, Kohda Y, Nonoguchi H, Misumi S, Maekawa Y, Murayama T, Tomita M, Tomita K. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. *Am J Kidney Dis* 2006; **48**: 151-154 [PMID: 16797398 DOI: 10.1053/j.ajkd.2006.04.062]

86 **Lomashvili KA**, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. *Kidney Int* 2009; **75**: 617-625 [PMID: 19129793 DOI: 10.1038/ki.2008.646]

87 **Nitta K**, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. *Am J Kidney Dis* 2004; **44**: 680-688 [PMID: 15384019]

88 **Hashiba H**, Aizawa S, Tamura K, Shigematsu T, Kogo H. Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. *Ther Apher Dial* 2004; **8**: 241-247 [PMID: 15154878 DOI: 10.1111/j.1526-0968.2004.00136.x]

89 **Toussaint ND**, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. *Am J Kidney Dis* 2010; **56**: 57-68 [PMID: 20347511 DOI: 10.1053/j.ajkd.2009.12.039]

90 **Tankó LB**, Qin G, Alexandersen P, Bagger YZ, Christiansen C. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. *Osteoporos Int* 2005; **16**: 184-190 [PMID: 15197541 DOI: 10.1007/s00198-004-1662-x]

91 **Kawahara T**, Nishikawa M, Kawahara C, Inazu T, Sakai K, Suzuki G. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. *Circulation* 2013; **127**: 2327-2335 [PMID: 23658438 DOI: 10.1161/CIRCULATIONAHA.113.001534]

92 **Wheeler DC**, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? *Kidney Int* 2013; **83**: 377-383 [PMID: 23325075 DOI: 10.1038/ki.2012.425]

93 **Kyriakopoulos G**, Kontogianni K. Sodium thiosulfate treatment of tumoral calcinosis in patients with end-stage renal disease. *Ren Fail* 1990; **12**: 213-219 [PMID: 2100824]

94 **Asplin JR**, Donahue SE, Lindeman C, Michalenka A, Strutz KL, Bushinsky DA. Thiosulfate reduces calcium phosphate nephrolithiasis. *J Am Soc Nephrol* 2009; **20**: 1246-1253 [PMID: 19369406 DOI: 10.1681/ASN.2008070754]

95 **Christie M**, Roscoe J, Chee J, Inparajah M, Vaughn-Neil T, Nagai G, Ng P, Fung J, Ting R, Tam P, Sikaneta T. Treatment of a hemodialysis patient with pulmonary calcification-associated progressive respiratory failure with sodium thiosulfate. *Transplantation* 2013; **96**: e1-e2 [PMID: 23807461 DOI: 10.1097/TP.0b013e3182958502]

96 **Nigwekar SU**, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E. Sodium thiosulfate therapy for calcific uremic arteriolopathy. *Clin J Am Soc Nephrol* 2013; **8**: 1162-1170 [PMID: 23520041 DOI: 10.2215/CJN.09880912]

97 **Pasch A**, Schaffner T, Huynh-Do U, Frey BM, Frey FJ, Farese S. Sodium thiosulfate prevents vascular calcifications in uremic rats. *Kidney Int* 2008; **74**: 1444-1453 [PMID: 18818688]

98 **Mathews SJ**, de Las Fuentes L, Podaralla P, Cabellon A, Zheng S, Bierhals A, Spence K, Slatopolsky E, Davila-Roman VG, Delmez JA. Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy. *Am J Nephrol* 2011; **33**: 131-138 [PMID: 21242673 DOI: 10.1159/000323550]

99 **Mataic D**, Bastani B. Intraperitoneal sodium thiosulfate for the treatment of calciphylaxis. *Ren Fail* 2006; **28**: 361-363 [PMID: 16771254]

100 **Lei Y**, Grover A, Sinha A, Vyavahare N. Efficacy of reversal of aortic calcification by chelating agents. *Calcif Tissue Int* 2013; **93**: 426-435 [PMID: 23963635 DOI: 10.1007/s00223-013-9780-0]

101 **Shearer MJ**, Fu X, Booth SL. Vitamin K nutrition, metabolism, and requirements: current concepts and future research. *Adv Nutr* 2012; **3**: 182-195 [PMID: 22516726 DOI: 10.3945/an.111.001800]

102 **Price PA**. Gla-containing proteins of bone. *Connect Tissue Res* 1989; **21**: 51-7; discussion 57-60 [PMID: 2691199]

103 **Palaniswamy C**, Sekhri A, Aronow WS, Kalra A, Peterson SJ. Association of warfarin use with valvular and vascular calcification: a review. *Clin Cardiol* 2011; **34**: 74-81 [PMID: 21298649 DOI: 10.1002/clc.20865]

104 **Cranenburg EC**, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Westerhuis R, Magdeleyns EJ, Herfs M, Vermeer C, Laverman GD. Vitamin K intake and status are low in hemodialysis patients. *Kidney Int* 2012; **82**: 605-610 [PMID: 22648294 DOI: 10.1038/ki.2012.191]

105 **Schlieper G**, Westenfeld R, Krüger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, Djuric Z, Damjanovic T, Ketteler M, Vermeer C, Dimkovic N, Floege J, Schurgers LJ. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. *J Am Soc Nephrol* 2011; **22**: 387-395 [PMID: 21289218 DOI: 10.1681/ASN.2010040339]

106 **Beulens JW**, Bots ML, Atsma F, Bartelink ML, Prokop M, Geleijnse JM, Witteman JC, Grobbee DE, van der Schouw YT. High dietary menaquinone intake is associated with reduced coronary calcification. *Atherosclerosis* 2009; **203**: 489-493 [PMID: 18722618 DOI: 10.1016/j.atherosclerosis.2008.07.010]

107 **Gast GC**, de Roos NM, Sluijs I, Bots ML, Beulens JW, Geleijnse JM, Witteman JC, Grobbee DE, Peeters PH, van der Schouw YT. A high menaquinone intake reduces the incidence of coronary heart disease. *Nutr Metab Cardiovasc Dis* 2009; **19**: 504-510 [PMID: 19179058 DOI: 10.1016/j.numecd.2008.10.004]

108 **Caluwe R**, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS. Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. *Nephrol Dial Transplant* 2013 [PMID: 24285428 DOI: 10.1093/ndt/gft464]

109 **McCabe KM**, Booth SL, Fu X, Shobeiri N, Pang JJ, Adams MA, Holden RM. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. *Kidney Int* 2013; **83**: 835-844 [PMID: 23344475 DOI: 10.1038/ki.2012.477]

110 **Krueger T**, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, Jacobi J, Jadoul M, Ketteler M, Rump LC, Stenvinkel P, Westenfeld R, Wiecek A, Reinartz S, Hilgers RD, Floege J. Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. *Nephrol Dial Transplant* 2013 [PMID: 24285427 DOI: 10.1093/ndt/gft459]

111 **Kalantar-Zadeh K**, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. *Kidney Int* 2006; **70**: 771-780 [PMID: 16820797 DOI: 10.1038/sj.ki.5001514]

112 **Naves-Díaz M**, Alvarez-Hernández D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andía JB. Oral active vitamin D is associated with improved survival in hemodialysis patients. *Kidney Int* 2008; **74**: 1070-1078 [PMID: 18633342 DOI: 10.1038/ki.2008.343]

113 **Shoji T,** Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population.[see comment]. *Nephrol Dial Transplant* 2004; **19**: 179-184

114 **Tentori F**, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, Akiba T, Greenwood RN, Kimata N, Levin NW, Piera LM, Saran R, Wolfe RA, Port FK. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. *Nephrol Dial Transplant* 2009; **24**: 963-972 [PMID: 19028748 DOI: 10.1093/ndt/gfn592]

115 **Melamed ML**, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. *Kidney Int* 2006; **70**: 351-357 [PMID: 16738536 DOI: 10.1038/sj.ki.5001542]

116 **Teng M**, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. *J Am Soc Nephrol* 2005; **16**: 1115-1125 [PMID: 15728786 DOI: 10.1681/ASN.2004070573]

117 **Tentori F**, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG. Mortality risk among hemodialysis patients receiving different vitamin D analogs. *Kidney Int* 2006; **70**: 1858-1865 [PMID: 17021609 DOI: 10.1038/sj.ki.5001868]

118 **Kovesdy CP**, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. *Arch Intern Med* 2008; **168**: 397-403 [PMID: 18299495 DOI: 10.1001/archinternmed.2007.110]

119 **Shoben AB**, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. *J Am Soc Nephrol* 2008; **19**: 1613-1619 [PMID: 18463168 DOI: 10.1681/ASN.2007111164]

120 **Sugiura S**, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Sendo S, Hamaguchi K, Nagaya H, Tatematsu M, Kurata K, Yuzawa Y, Matsuo S. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. *Clin Exp Nephrol* 2010; **14**: 43-50 [PMID: 19882205 DOI: 10.1007/s10157-009-0233-z]

 **P-Reviewers:** Aramwit P,Papagianni A **S- Editor: Ji FF L- Editor: E- Editor:**

**Table 1 Studies related to therapies that may influence arterial calcification and patient outcomes**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ref. | Subjects | N | Study type | Intervention | Follow-up(mo) | Results |
| Braun *et al*[[38](#_ENREF_38)] | HD  | 114 | RCT | Sevalamer *vs* calcium | 12 | ↓ CAC and AC |
| Chertow *et al*[[36](#_ENREF_36)] | HD | 200 | RCT | Sevelamer *vs* calcium | 12 | ↓ CAC  |
| Kakuta *et al*[[37](#_ENREF_37)] | HD | 183 | RCT | Sevelamer *vs* calcium | 12 | ↓ CAC  |
| Suki *et al*[[40](#_ENREF_40)] | HD | 2103 | RCT | Sevelamer *vs* calcium | 19 | ↔ mortality |
| Block *et al*[[2](#_ENREF_2)] | Incident HD | 127 | RCT | Sevelamer *vs*. calcium | 44 | ↓ mortality |
| Di lorio *et al*[[39](#_ENREF_39)]  | Incident HD | 466 | RCT | Sevelamer *vs* calcium | 24 | ↓ mortality |
| Block *et al*[[42](#_ENREF_42)] | Non-dialysis CKD | 148 | RCT | Sevelamer, lanthanum, calcium *vs* placebo | 9 | ↑ CAC and AC |
| Di lorio *et al*[[41](#_ENREF_41)] | Non-dialysis CKD | 212 | RCT | Sevelamer *vs* calcium | 24 | ↓ mortality |
| Lemos *et al*[[43](#_ENREF_43)] | Non-dialysis CKD | 38 | RCT | Rosuvastatin, sevelamer *vs* no drug | 24 | ↔ CAC |
| Toussaint *et al*[[49](#_ENREF_49)] | HD | 45 | RCT | Lanthanum *vs* calcium | 18 | ↓ AC |
| Wilson *et al*[[50](#_ENREF_50)] | HD | 1354 | RCT | Lanthanum *vs* calcium | 27 | ↔ mortality |
| Spiegel *et al*[[58](#_ENREF_58)] | HD | 7 | Observational | Combined magnesium-calcium | 18 | ↔ CAC |
| Kalanter-Zadeh *et al*[[111](#_ENREF_111)] | HD | 58058 | Retrospective | Paricalcitol *vs* no drug | 24 | ↓ mortality |
| Naves-Diaz *et al*[[112](#_ENREF_112)] | HD | 16004 | Retrospective | Alfacalcidol or calcitriol *vs* no drug | 16 | ↓ mortality |
| Shoji *et al*[[113](#_ENREF_113)] | HD | 242 | Prospective | Alfacalcidol *vs* no drug | 61 | ↓ CVD mortality |
| Tentori *et al*[[114](#_ENREF_114)] | HD | 38066 | Retrospective | Active vitamin D *vs* no drug | 60 | ↓ mortality |
| Melamed *et al*[[115](#_ENREF_115)] | Incident HD and PD | 1007 | Prospective | Calcitriol *vs* no drug | 30 | ↓ mortality |
| Teng *et al*[[116](#_ENREF_116)] | Incident HD | 51037 | Retrospective | Active D *vs* no drug | 24 | ↓ mortality |
| Tentori *et al*[[117](#_ENREF_117)] | Incident HD | 14967 | Retrospective | Calcitriol *vs* paricalcitol *vs* doxercalciferol *vs* no drug | 37 | ↓ mortality in all active D groups compared to no drug |
| Kovesdy *et al*[[118](#_ENREF_118)] | Non-dialysis CKD | 520 | Retrospective | Calcitriol *vs* no drug | 24 | ↓ mortality |
| Shoben *et al*[[119](#_ENREF_119)] | Non-dialysis CKD | 1418 | Retrospective | Calcitriol *vs* no drug | 24 | ↓ mortality |
| Sugiura *et al*[[120](#_ENREF_120)] | Non-dialysis CKD | 665 | Retrospective | Alfacalcidol *vs* no drug | 55 | ↓ CVD events and mortality |
| Thadhani *et al*[[75](#_ENREF_75)]Tamez *et al*[[76](#_ENREF_76)] | Non-dialysis CKD | 227196 | RCT | Paricalcitol *vs* placebo | 48 | ↔ left ventricular mass index↓ left atrial volume index |
| Raggi *et al*[[80](#_ENREF_80)] | HD | 360 | RCT | Cinacalcet + active D *vs* active D | 12 | ↓ CAC and aortic valve calcification |
| Evolve Trial[[83](#_ENREF_83)] | HD | 3883 | RCT | Cinacalcet *vs* placebo | 21 | ↔ CVD events or mortality |
| Hashiba *et al*[[88](#_ENREF_88)] | HD | 18 | RCT | Etidronate *vs* no drug | 6 | ↓ AC  |
| Nitta *et al*[[87](#_ENREF_87)] | HD | 35 | Observational | Etidronate | 12 | ↓ CAC  |
| Kawahara *et al*[[91](#_ENREF_91)] | GP | 108 | RCT | Atorvastatin *vs* Etidronate *vs* both | 12 | ↓ thoracic and abdominal aortic plaques in combined therapy |
| Adirekkiat *et al*[[33](#_ENREF_33)] | HD | 32 | Prospective | STS *vs* no drug | 9 | ↓ CAC |
| Mathews *et al*[[98](#_ENREF_98)] | HD | 22 | Observational | STS | 5 | ↓ CAC |

N: Number of patients; HD: Hemodialysis; PD: Peritoneal dialysis; CKD: Chronic kidney disease; RCT: Randomized controlled trial; CAC: Coronary calcification; AC: Aortic calcification.